

bs-12367R**[Primary Antibody]****TAZ Rabbit pAb**

Bioss
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn


techsupport@bioss.com.cn

400-901-9800


— DATASHEET —**Host:** Rabbit**Isotype:** IgG**Clonality:** Polyclonal**GeneID:** 25937**SWISS:** Q9GZV5**Target:** TAZ**Immunogen:** KLH conjugated synthetic peptide derived from human TAZ: 1-100/400.**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.


Background: The transcriptional co-activator with PDZ-binding motif (TAZ) is a 14-3-3-binding molecule. The highly conserved and ubiquitously expressed 14-3-3 proteins regulate differentiation, cell cycle progression and apoptosis by binding intracellular phosphoproteins involved in signal transduction. TAZ may link events at the plasma membrane and cytoskeleton to nuclear transcription in a manner that can be regulated by 14-3-3. TAZ shares homology with the WW domain of Yes-associated protein (YAP) and functions as a transcriptional co-activator by binding to the PPXY motif present on transcription factors. TAZ recognizes immunoreactive protein bands in lysates from MDCK, NIH-3T3 and 293T cells. In addition, COS7, Hep G2, CHO and HeLa cells express endogenous TAZ. 14-3-3 binding requires TAZ phosphorylation on a single Serine 89 residue, resulting in the inhibition of TAZ transcriptional co-activation through 14-3-3-mediated nuclear export.

Applications: WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (3ug/test)**Reactivity:** Human, Mouse, Rat**Predicted MW.:** 44 kDa**Subcellular Location:** Cell membrane ,Cytoplasm ,Nucleus**— VALIDATION IMAGES —**



Sample: MCF-7 (Human) Cell Lysate at 40 ug
Lovo(Human) CellLysate at 40 ug A549(Human)
CellLysate at 40 ug Primary: Anti-TAZ(bs-12367R)at 1/300 dilution Secondary: IRDye800CW Goat Anti-RabbitIgG at 1/20000 dilution Predicted band size: 44kD Observed band size: 46kD



Sample: Lane 1: Kidney (Mouse) Lysate at 40 ug
Lane 2: Kidney (Rat) Lysate at 40 ug Primary: Anti-TAZ (bs-12367R) at 1/1000 dilution Anti-beta-Actin (bs-0061R) at 1/2000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 50-55 kD Observed band size: 52 kD



Paraformaldehyde-fixed, paraffin embedded (mouse placenta); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (TAZ) Polyclonal Antibody, Unconjugated (bs-12367R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.



Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Paraformaldehyde-fixed, paraffin embedded (rat heart); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (TAZ) Polyclonal Antibody, Unconjugated (bs-12367R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.

Blank control:A549. Primary Antibody (green line): Rabbit Anti-TAZ antibody (bs-12367R) Dilution: 1µg /10⁶ cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-PE Dilution: 3µg /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20°C. The cells were then incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=4.6]** Jiaxu Zhou. et al. JTE-013 Alleviates Pulmonary Fibrosis by Affecting the RhoA/YAP Pathway and Mitochondrial Fusion/Fission. PHARMACEUTICALS-BASE. 2023 Oct;16(10):1444 WB ;Mouse. 37895915
- **[IF=4.5]** Shouying Xu. et al. ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway. INT J ONCOL. 2024 Aug;65(2):1-11 WB ;Human. 38873993
- **[IF=4.4]** Yiwei Wang. et al. Celastrol alleviates subconjunctival fibrosis induced by silicone implants mimicking glaucoma surgery. EUR J PHARM BIOPHARM. 2024 Jun;:114352 IF,WB ;Human. 38851459
- **[IF=4.4]** Yiwei Wang. et al. M2 macrophages promote subconjunctival fibrosis through YAP/TAZ signalling. ANN MED. 2024 Feb 09 WB ;Human. 38335557
- **[IF=2.8]** Xu Yue. et al. Tuina promotes nerve myelin regeneration in SNI rats through Piezo1/YAP/TAZ pathway. J ORTHOP SURG RES. 2025 Dec;20(1):1-12 IF ;Human. 40350445